Press Releases

Sonata Demonstrates Significant Advantages in Reducing Procedure Time, Length of Stay and Procedure Related Costs Compared to Myomectomy Redwood City, CA, June 30, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine

Positive Aspects of Transcervical Fibroid Ablation, Strong Clinical Results, Provides Facilities with Confidence in Treating Fibroids and Minimizing Potential Viral Risks – Procedural Volumes Increasing Redwood City, CA – June 22, 2020 - Gynesonics®, a women’s healthcare company focused on the

The Sonata System provides advantages in reducing the index procedure cost, length of stay (LOS), prescription medications, complications and radiology costs versus hysterectomy and myomectomy. Redwood City, CA – June 4, 2020 – Gynesonics, a women’s healthcare company focused on the development of

EARLY LAUNCH IN EUROPE CONTRIBUTES TO SIGNIFICANT PROCEDURAL GROWTH Redwood City, CA – May 28, 2020 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the

2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine

Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive

VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes  In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas)

Robust Outcomes Support the Potential of the Sonata System as a  First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as